Remodulin: The most prescribed parenteral PAH therapy1







FC=functional class; NYHA=New York Heart Association; PAH=pulmonary arterial hypertension.
Remodulin® (treprostinil) Injection
Indication
Remodulin is a prostacyclin vasodilator indicated for the treatment of pulmonary arterial hypertension (PAH; WHO Group 1) to diminish symptoms associated with exercise. Studies establishing effectiveness included patients with NYHA Functional Class II-IV symptoms and etiologies of idiopathic or heritable PAH (58%), PAH associated with congenital systemic-to-pulmonary shunts (23%), or PAH associated with connective tissue diseases (19%).

References: 1. Guidepoint Global, LLC. 40 PAH centers surveyed, last verified December 2016. 2. Remodulin [package insert]. Research Triangle Park, NC: United Therapeutics Corporation; 2018.